<DOC>
	<DOCNO>NCT02728453</DOCNO>
	<brief_summary>Patients type 2 diabetes mellitus expose excessive heart failure risk secondary leave ventricular hypertrophy impair diastolic filling , condition address currently available treatment . The abnormality result obesity-induced volume overload , increase blood pressure , myocardial fat accumulation . By improve metabolism , body weight , blood pressure , Empagliflozin address root cause type 2 diabetes-associated myocardial disease . We assess leave ventricular mass , function , lipid content patient type 2 diabetes mellitus use cardiac magnetic resonance imaging spectroscopy well echocardiography empagliflozin glimepiride treatment . We expect observe improvement leave ventricular mass , function , fat content empagliflozin . The result study help position empagliflozin antidiabetic agent add value protect heart .</brief_summary>
	<brief_title>SGLT2 Inhibition Left Ventricular Mass</brief_title>
	<detailed_description>Overview Medical Indication Type 2 diabetes mellitus associate increased heart failure risk . The increase risk result part poor glycemic control obesity , concomitant arterial hypertension may also contribute . In Framingham Heart Study , heart failure risk increase 5 % men 7 % woman 1 kg/m2 increment body mass index ( BMI ) . Compared normal weight subject , obese subject double heart failure risk . Given rapid increase prevalence obesity type 2 diabetes mellitus , number heart failure patient likely increase sharply . Evidence Heart failure obesity explain increase left ventricular mass impair leave ventricular diastolic fill rather systolic dysfunction . Obesity associated volume expansion increase cardiac output . Arterial blood pressure also increase increase obesity . In addition , type 2 diabetes mellitus may directly elicit abnormality myocardial metabolism function intramyocardial triglyceride deposition lipotoxicity . In study group , obese woman insulin resistance show increase myocardial lipid accumulation compare obese insulin-sensitive woman , intramyocardial lipid reduce dietary weight loss . Finally , intramyocardial lipid associate impaired diastolic function patient type 2 diabetes mellitus . Myocardial insulin resistance may also contribute heart failure , genetic deletion cardiac insulin receptor mice worsens catecholamine-mediated myocardial injury . Heart failure risk may exacerbate obesity-induced neurohumoral activation systemic inflammation . Inflammatory cytokine elevate heart failure modulate cardiac remodelling various mechanism include myocardial hypertrophy , fibrosis , apoptosis . Sodium-glucose cotransporter 2 ( SGLT2 ) inhibitors new drug class treatment type 2 diabetes mellitus . SGLT2 inhibitor may particularly suitable improve cardiac structure function substantially improve systemic glucose metabolism , low blood pressure , reduce body weight . These effect reduce sympathetic vasomotor tone , renin-angiotensin-system activity . Thus , SGLT2 inhibitor include empagliflozin ameliorate metabolic hemodynamic risk factor tightly link leave ventricular hypertrophy heart failure risk . Recently publish outcome data suggest beneficial effect empagliflozin heart failure hospitalisation rate overall cardiovascular mortality patient type 2 diabetes previously diagnose cardiovascular disease . Study Rationale Patients type 2 diabetes mellitus expose excessive heart failure risk secondary leave ventricular hypertrophy impair diastolic filling , condition address currently available treatment . The abnormality result obesity-induced volume overload , increase blood pressure , myocardial fat accumulation . By improve metabolism , body weight , blood pressure , empagliflozin address root cause myocardial disease associate type 2 diabetes- . We assess leave ventricular mass , function , lipid content patient type 2 diabetes mellitus 24 week treatment metformin plus empagliflozin glimepiride . We expect observe improvement leave ventricular mass , function , fat content empagliflozin . The result study help understand mechanism cardioprotective effect empagliflozin reveal recently .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>1. woman men ≥40 &lt; 80 year age 2. patient type 2 diabetes mellitus stable antidiabetic treatment last 3 month ; screen follow treatment condition allow : metformin + sulfonylurea HbA1c ≥6.5 % ≤9.0 % metformin monotherapy HbA1c ≥7.5 % ≤ 9.0 % metformin + dipeptidylpeptidaseIV inhibitor ≥6.5 % ≤9.0 % 3. waist circumference ≥80 cm woman ≥94 cm men 4. office blood pressure ≤150/95 mm Hg stable dose maximum 4 antihypertensive medication last 3 month ( 24h ambulatory blood pressure measurement ( ABPM ) allow check accuracy office value ; inclusion 24h mean blood pressure ≤145/90 mm Hg possible ) 5. woman without childbearing potential define : least 6 week surgical sterilization bilateral tubal ligation bilateral oophorectomy hysterectomy ≥ 50 year postmenopausal state &gt; 1 year &lt; 50 year postmenopausal state &gt; 1 year serum folliclestimulating Hormone ( FSH ) &gt; 40 IU/l serum estrogen &lt; 30 ng/l negative estrogen test , screen 6. woman childbearing potential negative serum pregnancy test screen agree meet one follow criterion time screening , study period 4 day follow last administration study medication : correct use reliable contraception method . The follow acceptable : hormonal contraceptive ( combined oral contraceptive , implant , transdermal patch , hormonal vaginal device injection prolong release ) , intrauterine device ( IUD/IUS ) double barrier method , e.g . condom occlusive cap ( diaphragm cervical/vault cap ) spermicide ( foam , gel , film , cream suppository ) true abstinence ( periodic abstinence withdrawal acceptable method contraception ) sexual relationship female partner sterile male partner 7. sign write informed consent willingness comply treatment followup 8. capability understanding investigational nature , potential risk benefit clinical trial 1. diabetes mellitus type 1 2. uncontrolled diabetes mellitus type 2 fast glucose &gt; 13.3 mmol/l confirm second day 3. previous treatment insulin , glucagonlike peptide1 analogue , pioglitazone last year screen 4. previous treatment empagliflozin 5. acute illness screen randomization accord judgement investigator patient 6. know suspected hypersensitivity empagliflozin , glimepiride excipients ; know suspected hypersensitivity sulfonylurea sulfonamides 7. history multiple severe hypoglycemic episode 8. condition prohibit MRI study ( e.g . metal implant , claustrophobia , body weight high ) include suspect reaction contrast agent application 9. patient actively attempt lose weight experience unintentional clinically significant weight loss last 3 month 10. bariatric surgery gastrointestinal surgery procedure induce chronic malabsorption 11. treatment weight loss drug precede 6 month 12. plan significant change prestudy physical activity level study participation 13. heart failure New York Heart Association ( NYHA ) III IV 14. patient know severe cardiovascular disease ( e.g . myocardial infarction , unstable angina , stable coronary artery disease , stroke transient ischemic attack ) 15. calculate glomerular filtration rate ( eGFR ) &lt; 60 ml/min/1,73 m2 16. treatment loop diuretic 17. chronic diarrhea , clinical sign volume depletion haematocrit &gt; 48 % ( woman ) &gt; 53 % ( men ) 18. history severe volume depletion require medical therapy 19. chronic low urinary tract infection ( simple asymptomatic bacteriuria ) 20. know acute chronic liver disease screen liver enzyme &gt; 3 x upper limit normal ( ULN ) 21. serum potassium &lt; 3.6 &gt; 5.0 mmol/l 22. glucose6phosphate dehydrogenase deficiency 23. anemia unknown origin 24. pregnancy lactation period 25. treatment systemic glucocorticoid last 3 month screen 26. chronic treatment nonsteroidal antiinflammatory drug ( NSAIDs ) 27. change thyroid hormone dosage ( stable dos thyroid hormone last 3 month acceptable ) 28. history drug alcohol abuse current abuse 29. psychosomatic psychiatric disease require hospitalization last 12 month ; ongoing treatment one tricyclic selective serotonin reuptake Inhibitor ( SSRI ) antidepressant drug stable dose since last 3 month acceptable except fluoxetine 30. medical history cancer except strictly localize tumor 31. medical surgical intervention plan next 7 month randomization allow study participation accord investigator´s judgment 32. current participation clinical trial participation another clinical trial within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>